Gilead Increases Investment In Arcus; Firms Abandon Chemo-Free Combo Study

 
• By Joseph Haas
  
Gilead HQ
Gilead increases its investment in Arcus and the anti-TIGIT mechanism • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business